Tag : NEOADJUVANT THERAPY

CONFERENCE UPDATE

Long-term survival benefit of pembrolizumab in high-risk early TNBC: Final analysis of the phase 3 KEYNOTE-522 study
Phase 3 KEYNOTE-522 data showed sustained pathological complete response, event-free survival, and overall survival improvements with perioperative pembrolizumab + chemotherapy vs. chemotherapy alone, alongside a manageable long-term safety profile, supporting its role as a standard-of-care option for patients with high-risk, early-stage triple-negative breast cancer (TNBC).